drugset / Trial / NCT02696291
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
Phase 1
Terminated
7 enrolled
Emergent BioSolutions
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
Timeline
- Start
- 2016-05-27
- Primary completion
- 2017-03-02
- Completion
- 2017-03-02
Outcome
Outcome not reported
Stopped (Business): “Product development halted for business reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UV-4B | Unknown | 30 mg | Oral |
| Subject | UV-4B | Unknown | 75 mg | Oral |
| Subject | UV-4B | Unknown | 150 mg | Oral |